Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2023

Cho Byoung Chul, Ahn Myung-Ju, Kang Jin Hyoung, Soo Ross A, Reungwetwattana Thanyanan, Yang James Chih-Hsin, Cicin Irfan, Kim Dong-Wan, Wu Yi-Long, Lu Shun, Lee Ki Hyeong, Pang Yong-Kek, Zimina Anastasia, Fong Chin Heng, Poddubskaya Elena, Sezer Ahmet, How Soon Hin, Danchaivijitr Pongwut, Kim YuKyung, Lim Yeji, An Taewon, Lee Hana, Byun Hae Mi, Zaric Bojan

Abstract excerpt

PURPOSE: Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally advanced or metastatic non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients were 18 years and older with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37379502
DOI: 10.1200/JCO.23.00515

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.PMID 37379502Read ↗

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.Semantic proximity Read ↗

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.Semantic proximity Read ↗

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.Semantic proximity Read ↗

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.Semantic proximity Read ↗

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.Semantic proximity Read ↗

Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.Semantic proximity Read ↗

Lazertinib: on the Way to Its Throne.Semantic proximity Read ↗

Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.Semantic proximity Read ↗

Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.Semantic proximity Read ↗

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.